(Q45206678)

10 December 2017

title

Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? (English)

1 reference

primary biliary cholangitis

10 December 2017

1 reference

0 references

author

Donald B Bloch

6

1 reference

10 December 2017

4

Donna Neuberg

1 reference

10 December 2017

Wei-Hong Yang

1

1 reference

10 December 2017

Jiang Hong Yu

2

1 reference

10 December 2017

Ayako Nakajima

3

1 reference

10 December 2017

Keith Lindor

5

1 reference

10 December 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

Clinical Gastroenterology and Hepatology

10 December 2017

published in

1 reference

10 December 2017

volume

2

1 reference

10 December 2017

issue

12

1 reference

10 December 2017

page(s)

1116-1122

1 reference

Primary biliary cirrhosis

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900465-3

7 January 2021

Primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900465-3

7 January 2021

The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900465-3

7 January 2021

Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900465-3

7 January 2021

Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900465-3

7 January 2021

Prognosis in primary biliary cirrhosis: model for decision making

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900465-3

7 January 2021

Adaptation of the Mayo primary biliary cirrhosis natural history model for application in liver transplant candidates

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900465-3

7 January 2021

Antimitochondrial antibodies in primary biliary cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900465-3

7 January 2021

Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900465-3

7 January 2021

Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900465-3

7 January 2021

Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900465-3

7 January 2021

Prevalence of IgA antibodies to endomysium and tissue transglutaminase in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900465-3

7 January 2021

Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900465-3

7 January 2021

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900465-3

7 January 2021

Range of antinuclear antibodies in "healthy" individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900465-3

7 January 2021

Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900465-3

7 January 2021

Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900465-3

7 January 2021

Scleroderma and primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900465-3

7 January 2021

Primary biliary cirrhosis with scleroderma, Raynaud's phenomenon and telangiectasia. New syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900465-3

7 January 2021

Anti-Centromere Antibody and CREST Syndrome in Patients with Primary Biliary Cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900465-3

7 January 2021

Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900465-3

7 January 2021

Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900465-3

7 January 2021

10.1016/S1542-3565(04)00465-3

Identifiers

DOI

1 reference

10 December 2017

1 reference